FMO3 anticorps (N-Term)

N° du produit ABIN3030969

Détail du produit anti-FMO3 anticorps

Antigène: FMO3 (Flavin Containing Monooxygenase 3 (FMO3))

Épitope: N-Term

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp FMO3 est non-conjugé

Application: Western Blotting (WB)

Purification: Antigen affinity

Immunogène: An amino acid sequence from the N-terminus of human Flavin-containing Monooxygenase 3 (DDFPNFMHNSKIQEY) was used as the immunogen for this FMO3 antibody.

Isotype: IgG

Information d'application

Indications d'application: The stated application concentrations are suggested starting amounts. Titration of the FMO3 antibody may be required due to differences in protocols and secondary/substrate sensitivity.\. Western blot: 0.5-1 μg/mL

Restrictions: For Research Use only

Stockage

Buffer: 0.5 mg/mL if reconstituted with 0.2 mL sterile DI water

Stock: -20 °C

Stockage commentaire: After reconstitution, the FMO3 antibody can be stored for up to one month at 4°C. For long-term, aliquot and store at -20°C. Avoid repeated freezing and thawing.

Détails sur FMO3

Antigène: FMO3 (Flavin Containing Monooxygenase 3 (FMO3))

Autre désignation: FMO3 (FMO3 Produits)

Synonymes: anticorps MGC107820, anticorps FMOII, anticorps TMAU, anticorps dJ127D3.1, anticorps FM03, anticorps AW111792, anticorps flavin containing monooxygenase 3, anticorps flavin containing monooxygenase 3 L homeolog, anticorps FMO3, anticorps fmo3, anticorps fmo3.L, anticorps Fmo3

Sujet: Flavin-containing Monooxygenase 3 is an enzyme that in humans is encoded by the FMO3 gene. The mammalian flavin-containing monooxygenases (FMOs) represent a multigene family whose gene products are localized in the endoplasmic reticulum of many tissues. Using quantitative RNase protection assays, FMO3 is present in low abundance in fetal liver and lung and in adult kidney and lung, and in much greater abundance in adult liver. By Western blot analysis of human liver microsomal samples ranging from 8 weeks gestation to 18 years of age, FMO1 is the major fetal isoform and FMO3 is the major adult isoform. Flavin-containing Monooxygenase 3 was expressed at intermediate levels until 11 years of age when a gender-independent increase in expression was observed during puberty. Sufferers of trimethylaminuria may display a reduced ability to metabolize substrates for FMO3 such as nicotine, amphetamine, clozapine, deprenyl, metamphetamine, tamoxifen, ethionamide, thiacetazone, and sulindac sulfide.

UniProt: P31513